Kahlua introduces iced coffee
NEW YORK — Kahlua has unveiled an on-the-go beverage for coffee lovers.
Kahlua Iced Coffee, which is 5% alcohol/volume per 200 ml can, delivers the artisanal taste of iced dark coffee using Kahlua’s locally sourced, 100% Arabica coffee beans from Veracruz, Mexico, and offers a premium new way to experience the sophisticated coffee-forward flavor of Kahlua.
"The portability of Kahlua’s new iced coffee makes it the perfect addition to summer parties, afternoon cookouts, or just to sip on the go," Kahlua brand director Michelle Sanders said. "The sleek and modern cans offer simple convenience in the form of pre-mixed Kahlua cocktails, which means hosts and party-goers can spend more time mingling and less time mixing drinks."
Avaialble in iced espresso, iced mocha and iced coffee with cinnamon spice, Kahlua Iced Coffee is available nationwide for a suggested retail price of $2.50 a can, or $9.99 for a four-pack.
Mike’s Hard Lemonade to introduce Winter Grab Bag for holiday season
SEATTLE — Mike’s Hard Lemonade is gearing up for the 2012 holiday season with the launch of its first-ever, limited-edition holiday variety pack.
Dubbed the Winter Grab Bag, Mike’s Hard Lemonade said the 12-count variety pack, which features 11.2-oz. glass bottles, will include winter blackberry, cranberry lemonade, as well as a brand new flavor, hard chocolate cherry, which only will be available in the limited-time variety pack.
"We pride ourselves on bringing unique flavors to consumers who rely on us to give them truly different and refreshing options in the beer aisle," Mike’s Hard Lemonade chief marketing officer Andy Horrow said. "Additionally, our retailers have been asking for this; through our Winter Grab Bag variety pack displays, we’re going to help them make incremental Mike’s sales this season."
The Mike’s Hard Lemonade Winter Grab Bag will carry a suggested retail price of $15.99 to $17.99, which will vary by market.
PhRMA: More than 100 drugs under development for mental illnesses
WASHINGTON — Nearly 200 drugs for mental illnesses are under clinical development or under review by the Food and Drug Administration, the largest trade group for the drug industry said Thursday.
The Pharmaceutical Research and Manufacturers of America released a report listing 187 drugs, including 52 for depression, 37 for schizophrenia and 26 for anxiety disorders.
"Mental illnesses do not discriminate and can have a profound impact on people’s lives," PhRMA president and CEO John Castellani said. "They come in many different forms and impact patients in many different ways. That is why biopharmaceutical research companies are working on new and better paths of treatment for patients battling these disabling conditions."